公开(公告)号：US20160271056A1

公开(公告)日：2016-09-22

申请号：US15035898

申请日：2014-12-11

Applicant: NITRIC SOLUTIONS INC. ,  12TH MAN TECHNOLOGIES, INC.

Inventor： Christopher Miller ,  Gilly Regev ,  Alex Stenzler

IPC: A61K9/00 ,  A61M16/12 ,  A61K33/00

CPC classification number: A61K9/0073 ,  A61K9/007 ,  A61K33/00 ,  A61M16/12 ,  A61M2202/0275 ,  A61M2202/0007

Abstract: One aspect of the invention provides a method of treating a subject diagnosed with cystic fibrosis, but not having a pathological bacterial colonization in either lung. The method includes administering gaseous nitric oxide at a concentration of between about 40 ppm and about 400 ppm to the subject's lungs wherein said nitric oxide is administered by inhalation, and further wherein said nitric oxide induces conformational change in the cystic fibrosis transmembrane conductance regulator (CFTR) in the cells of the lung of the subject. Another aspect of the invention provides a kit comprising: an apparatus for administering gaseous nitric oxide to a subject and instructions for administering the gaseous nitric oxide according to one or more of the methods described herein.

Abstract translation: 本发明的一个方面提供了一种治疗被诊断患有囊性纤维化但不在任一肺中具有病理性细菌定植的受试者的方法。 所述方法包括将浓度为约40ppm至约400ppm的气体一氧化氮施用于受试者的肺，其中所述一氧化氮通过吸入给药，并且其中所述一氧化氮诱导囊性纤维化跨膜传导调节因子（CFTR）中的构象变化 ）在受试者的肺的细胞中。 本发明的另一方面提供了一种试剂盒，其包括：根据本文所述的一种或多种方法向受试者施用气体一氧化氮的装置和用于施用气态一氧化氮的说明书。

公开(公告)号：US09730956B2

公开(公告)日：2017-08-15

申请号：US14643305

申请日：2015-03-10

Applicant: Nitric Solutions, Inc.

Inventor： Alex Stenzler ,  Christopher C. Miller ,  Gilly Regev-Shoshani

IPC: A61F13/00 ,  A61K33/00 ,  C01B21/24 ,  A61K9/00 ,  A61K47/12 ,  A61K9/08 ,  A61K9/70

CPC classification number: A61K33/00 ,  A61K9/0043 ,  A61K9/08 ,  A61K9/7007 ,  A61K47/12 ,  C01B21/24

Abstract: The present invention relates to a liquid nitric oxide releasing solution (NORS) comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of nitric oxide gas (gNO). The present invention also relates to a liquid NORS comprised of at least one nitrite compound having a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment of a wound in a human, the method comprising administering to the human a liquid NORS comprised of at least one nitric oxide releasing compound and at least one acidifying agent, wherein the NORS provides an extended release of a therapeutically effective amount of gNO. The present invention also relates to a method for the treatment, prevention, or reduction of incidence of a disease or disorder in a human in need thereof, the method comprising administering to the human a liquid NORS comprised of at least one nitrite compound at a concentration of no greater than about 0.5% w/v and at least one acidifying agent, wherein the NORS releases a therapeutically effective amount of gNO.